Category : InternationalPublished on: November 05 2021
Share on facebook
The United Kingdom became the first country to greenlight the Molnupiravir pill against Covid-19, which halves the risk of hospitalisation or death, developed by Merck and Ridgeback Biotherapeutics.
Currently, Molnupiravir is intended for vulnerable people who are experiencing mild to moderate Covid-19 symptoms and also have at least one other risk factor, such as obesity, heart problems or older age (over-60s).
The British government has ordered 500,000 treatments of the drug, which is sold under the brand name Lagevrio. The United States, Australia, Singapore and South Korea have also already placed orders.
Other pharmaceutical companies, such as Pfizer and the Swiss company Roche, are also working on similar anti-viral pills against Covid-19.
